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Effect of membrane fusion protein 
AdeT1 on the antimicrobial 
resistance of Escherichia coli
Victoria L. Barlow1, Shu‑Jung Lai2,3,4, Chia‑Yu Chen4, Cheng‑Han Tsai4, Shih‑Hsiung Wu4 & 
Yu‑Hsuan Tsai1*
Acinetobacter baumannii is a prevalent pathogen that can rapidly acquire resistance to antibiotics. 
Indeed, multidrug‑resistant A. baumannii is a major cause of hospital‑acquired infections and has been 
recognised by the World Health Organization as one of the most threatening bacteria to our society. 
Resistance‑nodulation‑division (RND) type multidrug efflux pumps have been demonstrated to 
convey antibiotic resistance to a wide range of pathogens and are the primary resistance mechanism 
employed by A. baumannii. A component of an RND pump in A. baumannii, AdeT1, was previously 
demonstrated to enhance the antimicrobial resistance of Escherichia coli. Here, we report the results 
of experiments which demonstrate that wild‑type AdeT1 does not confer antimicrobial resistance 
in E. coli, highlighting the importance of verifying protein production when determining minimum 
inhibitory concentrations (MICs) especially by broth dilution. Nevertheless, using an agar‑based 
MIC assay, we found that propionylation of Lys280 on AdeT1 renders E. coli cells more resistant to 
erythromycin.
Acinetobacter baumannii is a Gram-negative bacterium and opportunistic human pathogen which has become a 
prevalent source of hospital-acquired  infections1. Particularly, in intensive care units, A. baumannii accounts for 
10% of infections  worldwide2. Moreover, increasing rates of A. baumannii drug resistance has become a wide-
spread phenomenon since its first discovery in the  1970s1,3–5. Indeed, the World Health Organization recently 
highlighted that infections caused by drug-resistant A. baumannii are one of the most dangerous threats to 
human  society6.
Multidrug-resistant strains of A. baumannii harbour a genomic island containing up to 45 resistance genes, 
and sequence analysis suggests frequent exchange of genetic information between A. baumannii and other bacte-
rial  species7. Rapid acquisition of resistance has also been attributed to the high plasticity of protein expression in 
A. baumannii8,9. For example, loss of an outer membrane protein is associated with imipenem  resistance10,11. The 
dynamic protein expression allows the species to exhibit various resistance mechanisms, including degradation 
of drugs, modification of protein targets, and production of efflux  pumps5,12,13.
Multidrug efflux pumps play important roles in various bacterial interactions and maintenance of cell 
 homeostasis14. These pumps have evolved long before the use of antibiotics, which is very recent in terms of 
bacterial  evolution15. The pumps confer intrinsic, acquired, and induced resistance to  antibiotics16. They also 
have wider roles in infection, such as increased pathogenicity through transport of virulence factors and aid-
ing in biofilm  formation17. Not surprisingly, overexpression of pumps has been documented in many clinical 
 isolates13,18. In A. baumannii, basal-level expression of pumps is commonly observed and provides the bacteria 
with broad intrinsic  resistance12. This low-level resistance allows for selection of mutations in the regulatory 
genes controlling expression, inducing higher-level, acquired  resistance19–21.
Resistance-nodulation-division (RND) transporters are a major class of bacterial multidrug efflux  pumps14,22. 
They have wide substrate scope and represent the highest clinical relevance in multidrug resistant  bacteria23–25. 
At the molecular level, RND transporters have a tripartite structure, composed of an inner membrane protein, a 
membrane fusion protein, and an outer membrane protein. The three components interact with each other and 
form a functional transporter that extrudes a wide variety of toxic substrates from the  cell26,27. In A. baumannii, 
RND-type efflux pumps have been shown to confer resistance to a wide range of antibiotics and  detergents5,19,28. 
AdeABC was the first RND system characterised in A. baumannii29 and consists of the membrane fusion protein 
AdeA, inner membrane protein AdeB and outer membrane protein AdeC. Overexpression of adeABC was shown 
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to increase the resistance to a wide range of  substances29–34. This is also the case for two other RND pumps, 
AdeFGH and  AdeIJK33,34. Interestingly, it was reported that a single membrane fusion protein, AdeT1, could 
also increase the antimicrobial susceptibility of A. baumannii35. In addition to the native effects in A. baumannii, 
heterologous expression of adeABC, adeIJK or adeT1 in Escherichia coli have also been demonstrated to increase 
bacterial resistance to  antibiotics36. Indeed, bacterial resistance proteins are often functional in heterologous 
hosts, and E. coli has been commonly used for functional characterisation of antibiotic resistance proteins from 
other  bacteria37–39.
Intrigued by the function of AdeT1, here we show that overexpression of wildtype AdeT1, however, does 
not confer antimicrobial resistance in E. coli. We found that neither the plasmid nor the broth dilution method 
employed in the  literature35 led to production of AdeT1 protein in E. coli. Using a new plasmid and the agar 
method, we were able to achieve consistent production of wildtype AdeT1 protein, which, in contrast to the 
 literature35, did not confer antibiotic resistance to E. coli. Nevertheless, AdeT1 with propionylation at Lys280 
confers a fourfold increase in MIC of erythromycin to E. coli BL21(DE3) cells.
Results
Constructing a plasmid for producing AdeT1 protein in E. coli. While working on site-specific pro-
tein post-translational modification in A. baumannii40–42, we found propionylation of AdeT1 at Lys280 (K280pr) 
in two clinical isolates of SK17-S and SK17-R43 (Supplementary Fig. S1). As A. baumannii AdeT1 was reported 
by Srinivasan et al. to enhance antimicrobial  susceptibility35, we were interested in investigating whether this 
post-translational modification has functional significance. Particularly, post-translational modifications have 
been demonstrated to regulate different processes in  bacteria44–46.
Since heterologous expression of AdeT1 was shown to confer antimicrobial resistance in E. coli35, we set out 
to establish this heterologous functional assay, which has two clear advantages. Unlike handling of A. bauman-
nii, handling of a non-pathogenic E. coli strain poses minimum health and safety risks. In addition, genetic 
code expansion has been well established in E. coli, allowing site-specific incorporation of propionyl lysine for 
functional investigation of lysine  propionylation47,48.
Specifically, Srinivasan et al. reported that E. coli KAM32 overexpressing adeT1 increased bacterial resist-
ance to various  antibiotics35. This assertion was based on the minimum inhibitory concentration (MIC) values 
determined by broth dilution method. There, plasmid pAdeT1 was constructed from pUC18 for overexpressing 
adeT1, and MICs for erythromycin and chloramphenicol were reported to be 6- and 5-fold higher, respectively, 
in E. coli KAM32 carrying pAdeT1 than pUC18. E. coli KAM32 was chosen as it is hypersusceptible to antimi-
crobial agents due to the lack of major multidrug efflux pumps AcrB and  YdhE49.
We followed the experimental  procedure35 to construct pAdeT1 in house. As the adeT1 gene is under the 
control of the lac promoter, we expected protein production to be induced by the addition of isopropyl β-d-1-
thiogalactopyranoside (IPTG). However, we observed no AdeT1 protein in E. coli KAM32 carrying pAdeT1 
when analysed by SDS-PAGE (Supplementary Fig. S2). Analysis of pAdeT1 indicated that the adeT1 gene is not 
in frame with the open reading frame (Fig. 1). This could explain the lack of AdeT1 protein production, although 
we could not rule out the possibility of the protein produced at a low level, thus no prominent overexpression 
band in SDS-PAGE after Commassie Blue staining. To verify protein production via immunoblotting, which 
offers specificity and sensitivity over Commassie Blue staining, we constructed pAdeT1-His6, containing a His 
tag at the C-terminal of AdeT1 because there are no commercially available anti-AdeT1 antibodies. We also 
constructed pAdeT1*-His6, in which adeT1 is in frame with the open reading frame. Not surprisingly, protein 
of the expected size was only detected with the plasmid pAdeT1*-His6 after IPTG induction but not under any 
other conditions (Fig. 2 and Supplementary Fig. S3). We therefore concluded that the literature reported plasmid, 
Figure 1.  Extract of the plasmid map for the construct pAdeT1 employed by Srinivasan et al.35. In this 
construct, the adeT1 gene is not in frame with a start codon or the open reading frame of lacZα. It is unlikely 
that this construct can lead to production of AdeT1 protein.
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pAdeT1, is not functional for production of AdeT1 protein. Nevertheless, AdeT1 protein can be reproducibly 
produced in E. coli using plasmid pAdeT1*-His6.
As AdeT1 protein was produced by pAdeT1*-His6, we also generated plasmid pAdeT1*, where the adeT1 
gene is in the correct reading frame, but without a 6 × histidine tag at the C-terminus. To confirm whether AdeT1 
confers antimicrobial resistance in E. coli, we cultured E. coli KAM32 cells carrying either pUC18, pAdeT1* or 
pAdeT1*-His6 to  OD600 0.6, induced with IPTG, and waited 2 h after induction. The cells were then diluted 
into fresh media containing IPTG (to maintain protein production) and ampicillin (plasmid resistance marker) 
and underwent MIC testing in accordance with the CLSI microdilution  standard50. Puzzlingly, E. coli KAM32 
cells carrying either pUC18, pAdeT1* or pAdeT1*-His6 displayed no difference in MIC for chloramphenicol, 
erythromycin or tetracycline (Fig. 3 and Supplementary Tables S1–3 and Supplementary Fig. S4).
Protein production through inducible promoters is not maintained after broth dilution. As 
no difference in MIC was observed between control cells and those carrying pAdeT1* or pAdeT1*-His, we 
performed immunoblot analysis on cell samples from the end-point of MIC testing to confirm AdeT1 pro-
duction. Cells carrying pAdeT1*-His6 were diluted to low optical density 2 h post-induction with IPTG and 
cultured overnight in media containing ampicillin and IPTG. Production of AdeT1 protein was then analysed 
via immunoblotting against the C-terminal His tag. Intriguingly, AdeT1 production was not always detectable 
after dilution to low optical density and subsequent overnight incubation (Fig. 4 and Supplementary Fig. S5). 
We were not able to identify a condition in which AdeT1 is always present in the diluted culture after overnight 
incubation (Supplementary Fig. S6).
We then constructed an alternative plasmid, pET28a AdeT1*-His6, in which adeT1 is under the control of 
the commonly used T7 promoter. The T7 promoter induces high gene expression and we questioned whether 
this would allow more consistent protein production post induction. However, the lack of reproducible protein 
production after dilution was also observed with E. coli BL21(DE3) carrying pET28a AdeT1*-His6 (Supple-
mentary Fig. S7).
Figure 2.  Immunoblotting analysis of AdeT1 expression in E. coli KAM32 from three plasmids. The pAdeT1 
plasmid was constructed as described  before35, while pAdeT1-His6 contains a 6 × Histidine tag on the C 
terminus of the protein encoding gene. The pAdeT1*-His6 plasmid is a similar construct, with the adeT1 gene 
in frame with a start codon and with a 6 × Histidine tag on the C terminus. Cells were induced with 0.5 mM 
IPTG at  OD600 ~ 0.6. After 2 h at 37 °C, samples were taken for analysis. A full-length version of the immunoblot 
is provided in Supplementary Fig. S3.
Figure 3.  MIC testing of E. coli KAM32 cells carrying either pUC18, pAdeT1* or pAdeT1*-His6. Each data 
point represents an average of six biological replicates with the standard deviation. Optical density values 
were recorded on a Victor X (Perkin Elmer) microplate reader and converted to standard  OD600 values using a 
calibration curve. Averages and standard deviations of the raw data are provided in Supplementary Tables S1–3, 
while the  OD600 calibration curve is provided in Supplementary Fig. S4.
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To investigate if the lack of reproducible expression is unique to AdeT1 protein or a more generalised phe-
nomena, we performed the same experiments with pET28a sfGFP where similar results were obtained (Sup-
plementary Fig. S8). Thus, it appears that inducible lac and T7 promoters do not always work under dilution 
conditions. Attempts to determine MIC without prior dilution of the culture were not successful. Although 
protein was consistently detected after overnight incubation with antimicrobials, it was difficult to determine 
whether growth was inhibited or not (Supplementary Fig. S9).
Constitutively active promoters are not compatible for production of AdeT1. We envisaged that 
a constitutive promoter could address this problem. Thus, we constructed plasmids pAmpR-sfGFP, pLacUV5-
sfGFP and pLacI-sfGFP, in which expression of sfGFP is controlled by the constitutively active ampicillin resist-
ance gene (AmpR) promoter, the LacUV5 promoter or the lac repressor gene (LacI) promoter, respectively. The 
LacUV5 promoter was made constitutively active through removal of the regulatory lac operator. E. coli KAM32 
carrying a plasmid, in which sfGFP is under the control of AmpR or LacUV5 promoter, showed significantly 
higher green fluorescence (p < 0.05) than the wild-type cells (Fig. 5). In addition, the green fluorescence persisted 
in the diluted culture after overnight incubation. Puzzlingly, when sfGFP was directly replaced with adeT1*-
His6, no His-tagged protein was detectable by immunoblotting (Fig. 6 and Supplementary Fig. S10).
AdeT1 forms an active efflux pump in E. coli. To confirm whether AdeT1 protein forms an active 
efflux pump in E. coli, we performed a dye-based efflux assay with ethidium  bromide51. As shown in Fig. 7 and 
Supplementary Fig. S11, a significantly greater reduction in fluorescence can be observed in E. coli BL21(DE3) 
cells containing pET28a AdeT1*-His6 in comparison to control cells. For E. coli KAM32 cells, a similar trend 
was observed, however, the difference between control and AdeT1-producing cells was less pronounced and not 
significantly different, likely due to the relatively smaller amount of AdeT1 protein produced from the pAdeT1*-
His6 vector compared to pET28a AdeT1*-His6. Nevertheless, the results of the efflux assays suggest that the 
AdeT1 protein forms an active efflux pump in E. coli cells and is involved in export of ethidium bromide.
Production of wildtype AdeT1 does not increase the antimicrobial susceptibility of E. coli 
KAM32 or BL21(DE3). Due to the difficulty of maintaining protein production in diluted liquid cultures, 
we attempted to determine MIC using agar plates. As standard agar dilution  methods52 require dilution to low 
optical density, we modified the procedure and used a high density sample of bacterial cells. After IPTG induc-
tion for 2 h, a defined amount of E. coli KAM32 cells carrying pAdeT1*-His6 were concentrated to  OD600 4.0 and 
dropped onto agar plates containing IPTG, ampicillin, and varying concentrations of the test antibiotic (i.e. chlo-
ramphenicol, tetracycline or erythromycin). With this method, all colonies on the agar plates showed detect-
able and reproducible quantities of AdeT1 by immunoblotting. However, no difference in MIC was observed 
between E. coli KAM32 carrying pAdeT1*-His6 and E. coli KAM32 carrying pUC18 for either chloramphenicol, 
tetracycline or erythromycin (Fig. 8 and Supplementary Figs. S12 and S13). Furthermore, E. coli BL21(DE3) 
carrying either pET28a AdeT1*-His6 or pET28a also demonstrated no difference in antimicrobial susceptibility 
(Supplementary Figs. S14 and S15).
Production of propionylated AdeT1 decreases the antimicrobial susceptibility of E. coli 
BL21(DE3) to erythromycin. As AdeT1 can be propionylated at Lys280 in vivo (Supplementary Fig. S1), 
we investigated whether this post-translational modification had any effect on antimicrobial resistance in the E. 
coli model. AdeT1 with propionylated Lys280, AdeT1(K280pr), can be generated by genetic code  expansion47,48. 
In genetic code expansion, an orthogonal aminoacyl-tRNA synthetase/tRNA pair is introduced into the  cell53. 
The orthogonal synthetase recognises a specific unnatural amino acid, propionyl lysine (PrK) in this instance, 
Figure 4.  AdeT1 production was not always detectable after dilution of the induced culture to low optical 
density and subsequent overnight incubation in the presence of IPTG. E. coli KAM32 carrying pAdeT1*-His6 
were induced with 0.5 mM IPTG at  OD600 ~ 0.6. After 2 h, the induced culture was diluted to either  OD600 0.01 
or 0.001 in fresh media containing 0.5 mM IPTG and 100 μg/mL ampicillin (for plasmid selection). Three 
technical replicates were prepared for each dilution. Full blots are shown in Supplementary Fig. S5.
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Figure 5.  Fluorescence intensity of E. coli KAM32 cells containing sfGFP under the control of three constitutive 
promoters: AmpR, LacUV5 and LacI. Fluorescence was measured after incubation at 37 °C for 18 h (a), or 
after dilution of that culture to  OD600 0.01 and further incubation for another 18 h (b). Averages and standard 
deviations of two transformations, each with three technical replicates, are shown.
Figure 6.  Immunoblotting analysis of AdeT1 production under the control of constitutively active promoters. 
A single colony was cultured overnight in MHB, then diluted to  OD600 0.01 with three replicates and cultured 
overnight Full blots are shown in Supplementary Fig. S10.
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and loads it onto the orthogonal tRNA. The orthogonal tRNA is engineered to decode the amber stop codon 
(UAG). Thus, by mutating the codon of the corresponding amino acid residue to the amber codon, site-specific 
incorporation of PrK can be  achieved47,48.
Thus, we mutated the Lys280 codon to TAG in the adeT1 gene of both pAdeT1*-His6 and pET28a AdeT1*-
His6 to generate pAdeT1*(K280TAG)-His6 and pET28a AdeT1*(K280TAG)-His6, respectively. Each con-
struct was provided to the cells alongside a plasmid containing the corresponding orthogonal aminoacyl-tRNA 
Figure 7.  Efflux of ethidium bromide from E. coli BL21(DE3) cells expressing pET28a or pET28a AdeT1*-
His6. Each datapoint represents an average of three technical replicates, standard deviation is annotated for 
each average. The data shown is a representative example among four biological replicates. Results of the other 
biological replicates are shown in Supplementary Fig. S11.
Figure 8.  Antibiotic susceptibility of E. coli KAM32 carrying either pUC18 or pAdeT1*-His6. Data of two 
biological replicates (i.e. independent transformations), (1) and (2), are shown. E. coli KAM32 carrying either 
pUC18 or pAdeT1*-His6 were cultured to  OD600 0.6 before induction with 0.5 mM IPTG. After 2 h, a defined 
amount of cells were dropped on agar plates containing 0.5 mM IPTG, 100 µg/mL ampicillin and varying 
concentrations of chloramphenicol (top), tetracycline (middle) or erythromycin (bottom). Plates were incubated 
at 37 °C for 18 h before colonies of E. coli KAM32 carrying pAdeT1*-His6 were analysed by immunoblotting to 
confirm protein expression. Full-length blots are shown in Supplementary Figs. S12 and S13.
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synthetase/tRNACUA  pair, and PrK was supplemented into the growth media at the point of IPTG induction. 
Initial expression tests indicated that production of full-length AdeT1 protein containing PrK was more effective 
in E. coli BL21(DE3) cells with pET28a AdeT1*(K280TAG)-His6 than KAM32 cells with pAdeT1*(K280TAG)-
His6 (Supplementary Fig. S16).
While a chemiluminescent signal was detected in samples which were not provided with PrK (Supplementary 
Fig. S16), such signals were also detected when expressing sfGFP(150TAG) in the absence of propionyl lysine 
(Supplementary Fig. S17). Thus, the presence of full-length protein in the absence of propionyl lysine is likely 
the result of low-level incorporation of a canonical amino acid. Nevertheless, mass spectrometry confirmed the 
presence of PrK in AdeT1 in samples supplemented with the unnatural amino acid, and no wildtype or other 
species were observed (Supplementary Fig. S18).
Agar-based MIC tests were performed as described earlier with E. coli BL21(DE3) cells and the pET28a 
AdeT1*(K280TAG)-His6 construct. Intriguingly, the MIC of erythromycin required was fourfold higher when 
PrK was provided to the cells than the control (320 µg/mL and 80 µg/mL, respectively) (Fig. 9 and Supplementary 
Fig. S19). No difference in MIC was observed for tetracycline nor chloramphenicol (Supplementary Fig. S20). 
Two further antibiotics, ertapenem and ampicillin, were also tested and no difference in MIC was observed 
(Supplementary Fig. S20).
Discussion
An RND transporter has three components: an inner membrane protein, a membrane fusion protein, and an 
outer membrane  protein54. Membrane fusion proteins, such as AdeT1, alone are not functional for drug efflux. 
Nevertheless, components of an RND transporter can be functional in a heterologous host. For example, two 
components of Haemophilus influenzae multidrug efflux pump AcrAB were found to function with the E. coli 
outer membrane protein  TolC55. Similarly, Pseudomonas aeruginosa multidrug efflux pump MexXY can also 
assemble with E. coli TolC for drug  efflux56. In addition, P. aeruginosa MexB is an inner membrane protein that 
can complex with E. coli AcrA and TolC to form a tripartite  pump57. Thus, it would not be a surprise if AdeT1 
can form a functional pump with endogenous E. coli RND pump components as indicated in the  literature35. 
However, our results clearly showed that production of AdeT1 in E. coli did not enhance the bacterial resistance 
to either chloramphenicol or erythromycin (Fig. 8).
Constitutively active promoters have been successfully, albeit infrequently, employed in E. coli for producing 
recombinant  proteins58–63. We demonstrated that two constitutive promoters allowed constant production of 
sfGFP at low levels (i.e., no obvious green fluorescence in cultures by visual observation, in contrast to sfGFP 
under T7 promoter). However, we could not successfully produce AdeT1 using the same promoters, and the 
reason remains elusive.
The biggest obstacle we faced was maintenance of protein production after diluting post-induction cells to 
low optical densities. It was reported that dilution of E. coli BL21(DE3) may lead to chromosomal mutations, 
resulting in impaired production of functional T7 RNA  polymerase64. This could explain why our protein of 
interest was not reproducibly detected in diluted cultures.
Plasmid pAdeT1 employed by Srinivasan et al.35 for MIC determination also had a sequence frame-shift 
problem which was addressed in this report. Use of the agar method for MIC determination resulted in consist-
ent production of wildtype AdeT1 protein, which forms a functioning efflux pump capable of ethidium bromide 
efflux, but did not confer resistance in E. coli KAM32 or BL21(DE3) to either erythromycin, chloramphenicol 
or tetracycline. It is noteworthy that the commonly used broth dilution method in MIC determination may 
not frequently produce target protein with an inducer, which may cause unreliable MIC results. Therefore, we 
strongly recommend the confirmation of target protein expression when investigating relationships between 
target proteins and drug resistance.
Finally, AdeT1 protein is propionylated in A. baumannii in vivo. When propionylated AdeT1 protein is pro-
duced by E. coli BL21(DE3) cells, a fourfold increase in the MIC of erythromycin is observed. Such an increase 
in MIC was not observed for four other antibiotics tested. We therefore preliminarily report that propionyla-
tion may regulate the function of AdeT1 protein. However, it is important to note that only AdeT1 protein was 
Figure 9.  Antibiotic susceptibility of E. coli BL21(DE3) carrying pET28a AdeT1*(K280TAG)-His6 expressed 
either with or without propionyl lysine (PrK). Data of two biological replicates/independent transformations, 
(1) and (2), are shown. E. coli BL21(DE3) carrying pET28a AdeT1*(K280TAG)-His6 were cultured to  OD600 0.6 
before induction with 0.5 mM IPTG and supplementation with 5 mM PrK (as appropriate). After 2 h, a defined 
amount of cells were dropped on agar plates containing 0.5 mM IPTG, 5 mM PrK, 100 µg/mL spectinomycin, 
50 µg/mL kanamycin and varying concentrations of erythromycin. Plates were incubated at 37 °C for 18 h 
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heterologously produced in E. coli. Presumably, in A. baumannii the AdeT1 protein forms an efflux pump com-
plex with other RND-type proteins. When expressed in the heterologous E. coli host, AdeT1 may assemble with 
endogenous E. coli efflux pump components to form a pump complex which is not found in vivo55–57.
Therefore, the mechanism of erythromycin resistance in this instance may be a consequence of a pump com-
plex which does not form in nature, and propionylation of AdeT1 protein may not directly relate to erythromycin 
resistance in A. baumannii. Nevertheless, under these conditions, propionylation was able to modulate AdeT1 
function. Our results provide evidence in agreement with the growing body of literature reporting that in vivo 
post-translational modifications regulate protein function.
Methods
Plasmid construction. Plasmid pBAD sfGFP was a kind gift from Dr D. Dafydd Jones. The pET28a con-
trol plasmid for pET28a AdeT1*-His6 in our studies is plasmid pET28a sfGFP(150TAG) (Addgene plasmid 
#133455). After IPTG induction, a 16.8 kDa protein is produced. Plasmids used in this study are listed in Table 1. 
Tables 2 and 3 list primers for PCR and sequencing, respectively.
For cloning of pAdeT1, AdeT1 in a pUC18 vector was constructed as described by Bharathi Srinivasan et al.35 
The sequence was confirmed using primers YTS47 and YTS53.
For cloning of pAdeT1-His6, site-directed mutagenesis was performed to insert a 6 × Histidine tag at the 
C-terminus of the AdeT1 gene in pAdeT1 to construct pAdeT1-His6. The resulting sequence was confirmed 
using primers YTS47 and YTS53.
For cloning of pAdeT1*-His6, the adeT1 gene was amplified by PCR. The resulting 973 bp fragment was 
cloned into a pUC18 vector linearised with restriction enzymes EcoRI and BamHI using NEBuilder (New Eng-
land BioLabs, #E2621S) to afford pAdeT1*-His6. The plasmid sequence was confirmed using primers YTS47 
and YTS53.
For cloning of pAdeT1*, a 3597 bp fragment was amplified from plasmid pAdeT1*-His6 using primers 
VBF035 and VBR033. The resulting sequence was confirmed using primers YTS47 and YTS53.
For cloning of pET28a sfGFP-His6, both pET28a and pBAD sfGFP were digested with NcoI and XhoI to afford 
the vector and insert, respectively. The two fragments were assembled by T4 ligation. The resulting plasmid was 
sequenced with T7 promoter and T7 terminator primers.
For cloning of pET28a AdeT1*-His6, a 1000 bp fragment was PCR amplified and inserted into pET28a 
digested with BamHI and NcoI using NEBuilder (New England BioLabs, #E2621S). The resulting plasmid was 
sequenced with primers YTS30 and YTS52.
For cloning of pAmpR-sfGFP-His6 that constitutively expresses sfGFP by the AmpR (ampicillin resistance 
gene) promoter, a 3762 bp vector fragment was PCR amplified from pET21a using primers VBF004 and VBR004, 
and an 827 bp fragment containing sfGFP was PCR amplified from pBAD sfGFP using primers VBF005 and 
VBR005. The two fragments were assembled using NEBuilder (New England BioLabs, #E2621S) to afford pAmpR 
sfGFP, which was confirmed by sequencing with primers YTS14 and YTS15.
For cloning of pLacUV5-sfGFP-His6, a 3728 bp vector fragment was amplified from pET21a using primers 
VBF007 and VBR004. A 797 bp fragment was amplified from pBAD sfGFP using primers VBF005 and VBR007. 
The two fragments were assembled using NEBuilder (New England BioLabs, #E2621S). The resulting plasmid 
was subjected to site-directed mutagenesis with primers VBF015 and VBR015. The final plasmid was sequenced 
using primers YTS14 and YTS15.
Table 1.  Plasmids used in this study.
Plasmid Vector Insert Antibiotic selection Cloning sites Notes
pAdeT1 pUC18 adeT1 Ampicillin EcoRI, BamHI adeT gene is not in frame with start codon
pAdeT1-His6 pUC18 adeT1 Ampicillin
pAdeT1* pUC18 adeT1 Ampicillin
pAdeT1*-His6 pUC18 adeT1 Ampicillin BamHI, EcoRI
pET28a pET28a sfGFP (150TAG) Kanamycin Induction of this gene results in truncated sfGFP (16.8 kDa)
pET28a AdeT1*-His6 pET28a adeT1 Kanamycin BamHI, NcoI
pET28a sfGFP-His6 pET28a sfGFP Kanamycin NcoI, XhoI
pAmpR-sfGFP-His6 pET21a sfGFP Ampicillin
pLacUV5-sfGFP-His6 pET21a sfGFP Ampicillin LacUV5 promoter is constitutively active through removal of lac operator
pLacI-sfGFP-His6 pET21a sfGFP Ampicillin
pAmpR-AdeT1-His6 pET21a adeT1 Ampicillin NcoI, XhoI
pLacUV5-AdeT1-His6 pET21a adeT1 Ampicillin NcoI, XhoI LacUV5 promoter is constitutively active through removal of lac operator
pLacI-AdeT1-His6 pET21a adeT1 Ampicillin
pAdeT1*(K280TAG)-His6 pUC18 adeT1 (K280TAG) Ampicillin
pET28a AdeT1*(K280TAG)-His6 pET28a adeT1 (K280TAG) Kanamycin
pAcKST MbAcKRS, Pyl tRNA Spectinomycin MbAcKRS is a variant of MbPylRS with OOXX mutations
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For cloning of pLacI-sfGFP-His6, a 4536 bp fragment was amplified using primers VBF016 and VBR016 and 
directly transformed into E. coli Stbl3 where homologous recombination afforded plasmid pLacI-sfGFP-His6. 
The plasmid sequence was confirmed using primers YTS14 and YTS15.
For cloning of pAmpR-AdeT1-His6, the adeT1 gene was cloned downstream of the constitutively active 
ampicillin resistance promoter by replacing the sfGFP gene in pAmpR-sfGFP-His6 with AdeT1. The AdeT1 
gene was amplified via PCR using primers VBF020 and VBR019. The resulting 991 bp fragment was inserted 
into pAmpR-sfGFP-His6 digested with restriction enzymes XhoI and NcoI and assembled using NEBuilder 
(New England BioLabs, #E2621S). The resulting plasmid, pAmpR-AdeT1-His6, was sequenced using primers 
VBS014 and VBS017.
For cloning of pLacUV5-AdeT1-His6, the AdeT1 gene was amplified using primers VBF021 and VBR020 
and the resulting 1000 bp fragment was inserted into pLacUV5-sfGFP-His6 plasmid digested with restriction 
enzymes NcoI and XhoI. The two fragments were assembled using NEBuilder (New England BioLabs, #E2621S) 
and the resulting plasmid sequenced using primers VBS014 and VBS017.
For cloning of pLacI-AdeT1-His6, the AdeT1 gene was amplified using primers VBF022 and VBR020, result-
ing in a 1034 bp fragment and the pET21a vector was amplified using primers VBR016 and VBR004 to result in 
a 3717 bp plasmid. The two fragments were assembled using NEBuilder (New England BioLabs, #E2621S) and 
the resulting plasmid was sequenced using primers VBS014 and VBS017.
Table 2.  Primers for PCR.
Primer Sequence (5′–3′)
VBF004 GTT ATT GTC TCA TGA GCG GAT ACA TAT TTG AAT GTA TTT AGA AAA ATA AAC AAA TAG GGG TTC CGC GGA TCC AAG GAG GAA CTA TAT CCG GAT TGG CGA ATG G
VBR004 TAA AGC TCG AGA TCT GCA GCT GGC GCA ACG CAA TTA ATG TAA GTT AGC 
VBF005 CCA GCT GCA GAT CTC GAG CTT TAA TG
VBR005 GTA TCC GCT CAT GAG ACA ATA ACC CTG ATA AAT GCT TCA ATA ATA TTG AAA AAG GAA GAG TCC ATG GTT AGC AAA GGT GAA GAA CTG 
VBF007 CAA CAT ACG AGC CGG AAG CAT AAA GTG TAA AGA ATT CAA AGG AGG AAC TAT ATC CGG ATT GG
VBR007 TTT ACA CTT TAT GCT TCC GGC TCG TAT GTT GCC ATG GTT AGC AAA GGT GAA GAA CTG 
VBF015 ACA TTA TAC GAG CCG GAA GCA TAA AGT GTA AAG CCT GGG GTG CCT AAT GAG TGA GAA TTC AAA GGA GGA ACT ATA TCC GGA TTG G
VBR015 GCT TCC GGC TCG TAT AAT GTG TGG AAA AGC TTG GAT CCC ATG GTT TCA CAC AGG AAA CAG CTA TGG TTA GCA AAG GTG AAG AAC TG
VBF016 GAC ACC ATC GAA TGG CGC AAA ACC TTT CGC GGT ATG GCA TGA TAG CGC CCG GAA GAG AGT CAA TTC AGG GTG GTG AAT ATG GTT AGC AAA GGT GAA GAA CTG 
VBR016 TTG CGC CAT TCG ATG GTG TCG AAT TCA AAG GAG GAA CTA TAT CCG GAT TGG 
VBR019 CGT TGC GCC AGC TGC AGA TCT CGA GCT TCA GTG GTG GTG ATG ATG ATG TTC ATC GTT CAG G
VBF020 TGC TTC AAT AAT ATT GAA AAA GGA AGA GTC CAT GTT TGA TCC GAT TGG TAA AAG CGGTG 
VBR020 GCG CCA GCT GCA GAT CTC GAG CTT TAG TGG TGG TGA TGA TGA TGT TCA TCG TTC AGG 
VBF021 GTG TGG AAA AGC TTG GAT CCC ATG GTT TCA CAC AGG AAA CAG CTA TGT TTG ATC CGA TTG GTA AAA GCG GTG ATGC 
VBF022 GAC ACC ATC GAA TGG CGC AAA ACC TTT CGC GGT ATG GCA TGA TAG CGC CCG GAA GAG AGT CAA TTC AGG GTG GTG AAT ATG TTT GAT CCG ATT GGT AAA AGC GGT GAT GC
VBR025 GGG ATC ATA AAT ACC TGC TTT GGT C
VBF027 AAG CAG GTA TTT ATG ATC CCT AGA TGA TGA ACT TCC TGA AGA AAG TGC 
VBR033 TGC AGG TCG ACT CTA GAG TCA TTC ATC GTT CAG GGC ACA TTC 
VBF035 TGA CTC TAG AGT CGA CCT GCAG 
SPF001 TTC ATC ATC TAG GGA TCA TAA ATA CCT GCT TTG GTC AG
SPR001 TAT GAT CCC TAG ATG ATG AAC TTC CTG AAG AAA GTG C
Table 3.  Primers for sequencing.
Primer Sequence (5′–3′)
YTS14 CCG ATT CTG GTG GAA CTG 
YTS15 TAG GTC AGG GTG GTCAC 
YTS30 ATG GTG TCC GGG ATCTC 
YTS47 GCC TTT TGC TCA CAT GTT C
YTS52 TTA ATG CGC CGC TACAG 
YTS53 AAA TAC CGC ACA GATGC 
VBS014 CAT TGG TCC GGC ATACC 
VBS017 CAA TCG GTG CCG GAAC 
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For cloning of pAdeT1*(K280TAG)-His6, site-directed mutagenesis was used to mutate the lysine codon at 
position 280 to the amber stop codon (TAG) using forward primer VBF027 and reverse primer VBR025. The 
resulting plasmid was sequenced with primers VBS014 and VBS017.
For cloning of pET28a AdeT1(K280TAG)-His6, site directed mutagenesis was used to construct plasmid 
pET28a AdeT1(K280TAG)-His6 using forward primer SPF001 and reverse primer SPR001 with pET28a AdeT1-
His6 as a template. The resulting plasmid was sequenced with primers YTS30 and YTS52.
Identification of AdeT1 propionylation. Data41 obtained from the acetylome studies of A. baumannii 
SK17-S and SK17-R were analysed for lysine propionylation using the procedure described  before42.
Expression trials. The bacterial strain E. coli TG1 KAM32 (ΔacrB, ΔydhE) was used for this study and pro-
vided as a kind gift from Professor Teruo Kuroda, Hiroshima University. E. coli BL21(DE3) cells were also used 
when T7 expression was required.
Efflux assays. Ethidium bromide efflux assays were performed as described by Viveiros et al.51 with 0.5 mM 
IPTG added to cultures at  OD600 0.6 before centrifugation, and included in the PBS used during ethidium bro-
mide accumulation. For the efflux pump inhibitor, 100 µg/mL 1-(1-naphthylmethyl)-piperazine was used. Each 
experiment contains three technical replica for each condition, and four biological repeats of each experiment 
were conducted. Fluorescence measurements were obtained with a FLUOStar (Optima) plate reader (ex 500, em 
590, gain 4095).
Inducible expression. For all expressions, a starter culture was prepared by inoculating a single colony into 
5 mL Mueller Hinton Broth (MHB) (Sigma-Aldrich #70192) + 100 µg/mL ampicillin or 50 µg/mL kanamycin, 
as appropriate, and at 37 °C, 180 rpm for 18 h. The starter culture was then diluted in fresh MHB + 100 µg/mL 
ampicillin/50 µg/mL kanamycin to an  OD600 of 0.05 and incubated at 37 °C, 180 rpm. At  OD600 0.6, cultures were 
induced with 0.5 mM IPTG and incubated for 1–2 h at 37 °C, 180 rpm before use in MIC testing.
MIC tests. Microdilution studies were performed in accordance with CLSI microdilution  protocols50. Spe-
cifically, cells were diluted to  OD600 0.02 in fresh MHB containing 100 µg/mL ampicillin and 0.5 mM IPTG. This 
inoculum (50 μL) was then added to a 96 well microplate, with each well containing 50 µL of MHB containing 
100 µg/mL ampicillin, 0.5 mM IPTG and varying concentrations of the test antibiotic. Plates were incubated 
at 37 °C for 16–20 h before MIC was determined. MIC is defined as the minimum concentration of antibiotic 
required to visually inhibit bacterial growth as observed by the unaided eye. Visual observations were further 
supported by measurement of the  OD600 of each well on a Victor X (Perkin Elmer) plate reader.
When MIC was tested without prior dilution of the culture, the culture was divided into 10 mL fractions 2 h 
post-induction, and chloramphenicol added directly. The culture was then incubated for 18 h at 37 °C, 180 rpm 
before  OD600 was measured.
For agar MIC methods, the  OD600 of 2 h post-induction cultures were ~ 1–1.2. At this point, the cultures were 
normalised  OD600 4.0. This was achieved by pelleting the cells and removing some of the supernatant so that 
when resuspended, the cells would be the required  OD600. Then, 20 µL of these adjusted cultures were dropped 
onto LB agar plates containing 0.5 mM IPTG, 100 µg/mL ampicillin or 50 µg/mL kanamycin as appropriate, and 
various concentrations of test antibiotic, and incubated at 37 °C for 18 h.
Propionyl lysine incorporation. Appropriate plasmid containing adeT1 gene with a TAG codon muta-
tion was co-transformed with a plasmid containing acetyl lysine synthetase and 1 copy of a corresponding tRNA 
(pAcKST). MIC testing was performed as before, with 5 mM PrK added to the culture at the point of induction 
with IPTG, and included in the antibiotic-testing agar plates.
Constitutive expression. A single colony was used to inoculate 5 mL MHB containing 100 µg/mL ampi-
cillin and incubated for 18 h at 37 °C, 180 rpm. The culture was then diluted to  OD600 0.01 into 5 mL fresh MHB 
containing 100 µg/mL ampicillin and 100 µL of this dilution was plated in triplicate into a 96-well plate and 
incubated for 18 h at 37 °C, 180 rpm.
Immunoblotting analysis. Samples from liquid cultures were taken by normalising the  OD600 to 1.5 and 
taking 1 mL. Cells were then pelleted and resuspended in 50 µL of SDS loading dye (50 mM Tris–Cl (pH 6.8); 
2% (w/v) sodium dodecyl sulfate; 0.1% (w/v) bromophenol blue; 10% (v/v) glycerol; 100 mM dithiothreitol). 
For low volume liquid cultures where normalising the  OD600 was not possible, the whole culture was pelleted 
and resuspended in 10 µL loading dye. For solid cultures from agar plates, the whole colony was resuspended 
in phosphate buffered saline (PBS, 50 mM NaPi, 150 mM NaCl pH 7.4), pelleted and resuspended in 10–50 µL 
loading dye depending on cell density of colony.
Samples were heated (95 °C, 5 min) and 10 µL of all samples were loaded onto 12% SDS-PAGE and electro-
phoresed with 155 V, 55 mA, for 1 h. The gel was transferred to a 0.2 µM nitrocellulose membrane (#1704158) 
using a Trans-Blot Turbo Transfer System (BioRad #1704150) with mixed molecular weight setting applied. 
Membrane was then stained with Ponceau S (0.1% Ponceau S in 5% acetic acid), then blocked in 5% (w/v) 
milk (Sigma-Aldrich #70166) PBST (0.05% (v/v) Tween 20 in PBS) for 1–2 h at 18 °C with gentle agitation. 
Membrane was then transferred to 5% milk PBST containing primary mouse 6x-His tag monoclonal antibody 
(ThermoFisher #MA121315, 1:1000 (v/v) dilution) and incubated overnight at 4 °C. Membrane was then washed 
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for 5 min in PBST 3 times, before incubation with 5% milk PBST containing goat anti-mouse IgG (H + L) second-
ary antibody (ThermoFisher #32430, 1:1000 (v/v) dilution) for 1–2 h at 18 °C with gentle agitation. Membrane 
was then washed for 5 min in PBST 3 times. Signal was developed using Clarity Max (Bio-Rad #1705062) and 
imaged using a ChemiDoc XRS + system (Bio-Rad #1708265).
Fluorescence intensity measurements. Overnight samples were taken by normalising the  OD600 to 
1.5 and taking 1 mL of culture, which was pelleted and resuspended in 1 mL PBS. For each sample, 100 µL was 
loaded in triplicate onto a 96 well plate (Fisher Scientific #167008). Samples from cultures grown in a 96-well 
plate were taken by centrifuging cultures in plate, discarding supernatant and resuspending in 100 µL PBS. 
 OD600 was measured on a Victor X (Perkin Elmer) plate reader using the  OD600 protocol (CW-lamp OG590, 
filter B7) with 5 s shaking before measurement. Fluorescence intensity was measured on FLUOstar (Optima) 
plate reader (ex 485, em 520, gain 804).
Equipment and settings. All images were taken with a ChemiDoc XRS + system (Bio-Rad #1708265) and 
processed using Image Lab software (Biorad). For MIC testing, pictures of colonies were taken using the white 
light conversion screen and all images were adjusted identically to enhance the contrast and visibility of colonies 
by using the ‘Image Transform’ tool and setting ‘High’ to 41,215 and ‘Low’ to 8192. For immunoblots, images of 
Ponceau S stains may have contrast adjusted to increase band visibility. Images of chemiluminescent signal have 
not had any adjustment made although may be cropped in the main manuscript. Original, uncropped versions 
of all blots can be found in the Supplementary Information.
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information file (Supplementary Figs. S1–S20). Information on the original data underpinning the results pre-
sented here, including how to access them, can be found in the Cardiff University data catalogue at https ://doi.
org/10.17035 /d.2020.01203 68784 .
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